tolmetin has been researched along with Uterine Diseases in 2 studies
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.
tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.
Uterine Diseases: Pathological processes involving any part of the UTERUS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| LeGrand, EK | 1 |
| Rodgers, KE | 1 |
| Girgis, W | 1 |
| Struck, K | 1 |
| Campeau, JD | 1 |
| diZerega, GS | 1 |
| Kiorpes, TC | 1 |
| Diemunsch, P | 1 |
| Alt, M | 1 |
| Diemunsch, AM | 1 |
| Treisser, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery[NCT03805607] | Phase 4 | 40 participants (Actual) | Interventional | 2021-01-18 | Active, not recruiting | ||
| A Prospective, Randomized, Control Trial of Ketorolac Versus Placebo on Opioid Analgesic Use, Estimated Blood Loss and Complications Following Cesarean Delivery With Epidural Morphine[NCT02509312] | Phase 4 | 70 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total doses of medications to treat pruritus (opioid side-effect) including ondansetron and promethazine. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | doses (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Corrected change in Hct on POD1. Performed by subtracting POD1 Hct from POD0 Hct. Correction for transfusion by further subtracting 3 per unit of pRBC transfused to account for the typical change seen per unit transfused. (NCT02509312)
Timeframe: POD1
| Intervention | mg/dl (Mean) |
|---|---|
| Ketorolac | -5.1 |
| Placebo | -3.5 |
Estimation of blood loss during surgery (NCT02509312)
Timeframe: Immediately post-op
| Intervention | ml (Median) |
|---|---|
| Ketorolac | 900 |
| Placebo | 800 |
Rate of Post-Partum Hemorrhage between groups during the first 24 hours pst-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac | 7 |
| Placebo | 4 |
Total doses of medications to treat pruritus (opioid side-effect) including diphenhydramine, nalbuphine and naloxone. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | doses (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Total hydromorphone doses in mg in the first 24 hours post-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum.
| Intervention | mg (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0.2 |
Total number of Units of Packed Reb Blood Cell Transfused in intra-op until 24 hours post-partum. (NCT02509312)
Timeframe: Intra-op until 24 hours post-partum.
| Intervention | units of pRBCs (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Total number of uterotonic doses including methylergonovine, carboprost and misoprostol. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | doses (Median) |
|---|---|
| Ketorolac | 0 |
| Placebo | 0 |
Pain score post-Cesarean Delivery using 11-point numerical rating scale (NRS): 0-10 where 0 is no pain and 10 is the worst pain imaginable (NCT02509312)
Timeframe: Up to 24 hours post-cesarean delivery
| Intervention | units on NRS (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | 15 mins | 1 hour | 6 hours | 12 hours | 24 hours | |
| Ketorolac | 0 | 0 | 0 | 1 | 2 | 4.5 |
| Placebo | 0 | 0 | 0 | 3 | 3.5 | 5.5 |
Percentile change in diastolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | Percent change (Mean) | ||
|---|---|---|---|
| 6 hours | 12 hours | 24 hours | |
| Ketorolac | 12.30 | 8.8 | 12.0 |
| Placebo | 7.6 | 8.8 | 11.1 |
Percentile change in Systolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
| Intervention | Percent change (Mean) | ||
|---|---|---|---|
| 6 hours | 12 hours | 24 hours | |
| Ketorolac | -2.0 | -9.10 | -5.9 |
| Placebo | -0.6 | -2.85 | -3.5 |
2 other studies available for tolmetin and Uterine Diseases
| Article | Year |
|---|---|
Efficacy of tolmetin sodium for adhesion prevention in rabbit and rat models.
Topics: Animals; Female; Peritoneal Diseases; Rabbits; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Tolmeti | 1994 |
Post cesarean analgesia with ketorolac tromethamine and uterine atonia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Female; Humans; Ketorolac Trometha | 1997 |
Post cesarean analgesia with ketorolac tromethamine and uterine atonia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Female; Humans; Ketorolac Trometha | 1997 |
Post cesarean analgesia with ketorolac tromethamine and uterine atonia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Female; Humans; Ketorolac Trometha | 1997 |
Post cesarean analgesia with ketorolac tromethamine and uterine atonia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Female; Humans; Ketorolac Trometha | 1997 |